SciELO - Scientific Electronic Library Online

 
vol.60 número2Evaluación cualitativa y cuantitativa de ensañanza aprendizaje combinado, sobre alimentación del menor de dos años índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Cuadernos Hospital de Clínicas

versión impresa ISSN 1562-6776

Resumen

CRUZ-GUISBERT, J R. Survival analysis of patients with breast cancer: in the Hospital Seguro Social Universitario, term 2000 to 2016. Cuad. - Hosp. Clín. [online]. 2019, vol.60, n.2, pp.39-45. ISSN 1562-6776.

Abstract OBJECTIVE: To determine the survival ofpatients with breast cancer in the University Social Security Hospital, from term 2000 to 2016 METHOD: Mixed cohort study RESULTS: Survival of patients with breast cancer, had an average survival time of 104 months (8,6 years), in Hormonal cases (+) who received treatment with Exemestane, after Adriamycin and Cyclophosphamide survival time was 99,5 months (IC 83,2 -115,78). In contrast, in patients with breast cancer Herb New (-) treated with Trastuzumab, after receiving Adriamycin and Cyclophosphamide was 103,28 months (IC 86,54 -120,024). The median survival time was 104,13 months. The only factor that predicts the survival of patients with breast cancer, in this study was the histological type (p = 0,026), with a relative risk of 17,6. CONCLUSIONS: The survival of patients with breast cancer, treated at the University Social Security Hospital, from the term 2000 to 2016, was 8.6 years, a result equivalent to those reported in the literature.

Palabras clave : Survival; Breast cancer.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons